LMR Partners’s Viking Therapeutics VKTX Stock Holding History

LMR Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-24,100	Closed	-$1.98M	–	1324
2024 Q1	$1.98M	Buy	+24,100	New	+$1.07M	0.02%	548

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LMR Partners's VKTX Position: Q1 2025 in Review

LMR Partners sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 5,000 shares — an estimated $158K sold.

LMR Partners first reported a position in VKTX in Q3 2018 and held it in 6 quarters. The position peaked at $371K in Q1 2023. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

LMR Partners reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 5,000 Viking Therapeutics shares in Q1 2025, an estimated $158K.
LMR Partners first reported a position in Viking Therapeutics in Q3 2018 and held it in 6 quarters.
LMR Partners's Viking Therapeutics position peaked at $371K in Q1 2023.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.